These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 24054933)

  • 1. Androgens and prostate cancer; pathogenesis and deprivation therapy.
    Grossmann M; Cheung AS; Zajac JD
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.
    Ishizaki F; Hara N; Takizawa I; Nishiyama T; Isahaya E; Kawasaki T; Takahashi K
    Growth Horm IGF Res; 2012; 22(3-4):122-8. PubMed ID: 22579549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
    Kim HS; Freedland SJ
    Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
    Schulman C; Irani J; Aapro M
    BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
    Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy.
    Maggio M; Blackford A; Taub D; Carducci M; Ble A; Metter EJ; Braga-Basaria M; Dobs A; Basaria S
    J Androl; 2006; 27(6):725-8. PubMed ID: 16775253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.